James Barder, chief executive of Futura Medical plc (), tells Proactive they've begun recruitment for a pharmacokinetic study of their lead product, MED2002.
It's a prelude to starting phase III trials of the breakthrough gel for erectile dysfunction.
Data from 40 men will determine the doses used in the final-stage clinical assessment, which will kick off as “soon as practicable” after the current programme.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Futura Medical PLC named herein, including the promotion by the Company of Futura Medical PLC in any Content on the Site, the Company receives...
FOR OUR FULL DISCLAIMER CLICK HERE